Better progression-free survival with ibrutinib regimens in untreated older CLL patients
Treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression-free survival among older patients with untreated chronic lymphocytic leukemia (CLL). The study published December 27, 2018 in the New England Journal of Medicine found no significant difference between ibrutinib and ibrutinib plus rituximab with regard to progression-free survival.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies